Ryoncil Q4 Revenue of $36M Drives Full-Year Total to $115M, Topping Mesoblast's Projections
MESO sits 43% above its 52-week low of $10.38.
Summary
Mesoblast reported Ryoncil net revenue of $36M for Q4 and $115M for the full year ended June 30, 2026, exceeding initial projections and underscoring strong commercial momentum.
Key Events · Earnings and Guidance · MESO
-
Ryoncil Q4 Revenue Hits $36M
Driven by strong uptake in major U.S. pediatric centers, net revenue reached US$36 million for the quarter ended June 30, 2026.
-
Full-Year Revenue Reaches $115M
The first full year of Ryoncil sales generated US$115 million, exceeding management's initial projections.
-
Revenue Growth Funds Operations
Operational activities are now well funded through revenue growth, the CEO noted, reducing near-term capital needs.
-
Strategic Flexibility from Debt Facility
A new five-year $50 million facility frees up label extension and blockbuster products for strategic initiatives.
Analysis · MESO · Life Sciences
Ryoncil's first full year on the market delivered $115M in net revenue, with $36M coming in Q4 alone — well above initial projections. The strong uptake across major U.S. pediatric centers validates the commercial launch of the first FDA-approved MSC therapy. With operations now funded by revenue and a new $50M debt facility in place, the company has the financial headroom to pursue label expansions and pipeline assets without near-term dilution risk.
How filings like this one have moved
In the 30 days to Aug 24, 2026, 37.5% of the 3362 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MESO was trading at $14.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $10.38 to $21.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.